We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sanofi and ImmuNext have announced an agreement focused on the development of a novel antibody with the potential to treat a range of autoimmune diseases including lupus and multiple sclerosis.